摘要
目的研发能提高HER2阳性乳腺癌热疗效应的核酸适配体-铁纳米粒子复合体(AptNPs),探索肿瘤靶向治疗的全新途径。方法利用生物素和链霉亲和素的结合反应构建AptNPs,用动态光散射粒径仪表征其尺寸分布,用流式细胞仪和相差显微镜检测AptNPs的靶向结合能力,MTS法测其对磁场下抗肿瘤热疗效果的影响。结果通过生物素-亲和素反应构建了AptNPs,其平均直径为333.7 nm,对HER2阳性细胞有较强的结合,对HER2阴性细胞没有结合。此外,AptNPs可显著提升对HER2阳性细胞的热疗杀伤率(P<0.05),但对HER2阴性细胞的热疗后杀伤率影响较小。结论 AptNPs能靶向性地提升针对HER2阳性肿瘤细胞的热疗效率,在研发新型肿瘤靶向热疗方面具有潜在应用价值。
Objective To develop aptamer-modified nanoparticles （AptNPs） for targeted enhancement of thermal damage to HER2-positive breast cancer cells.Methods HER2 aptamer was connected to NPs via biotin-streptavidin reaction.AptNPs were characterized by Dynamic Light Scattering （DLS）.The binding feature of the aptamer was evaluated by flow cytometry,and the affinity of AptNPs to target cells by phase-contrast microscopy.Thermal damage under alternative magnetic field was measured by MTS assay.Results The average size of AptNPs was 333.7 nm.AptNPs exhibited strong binding to the HER2-positive but not the HER2-negative cells.Importantly,AptNPs enhanced the thermal damage to the HER2-positive tumor cells,but not that to the HER2-negative cells.Conclusions Aptamer-guided iron particles may have potential utility in development of novel HER2-targeted thermal therapies.
出处
《基础医学与临床》
CSCD
北大核心
2014年第5期644-647,共4页
Basic and Clinical Medicine
基金
科技部重大科学计划(2011CB933504
2011CB911004
2011CB911003)
